AI and Informed Consent in Clinical Settings: The Black Box Disclosure Problem

A physician uses an AI-powered diagnostic imaging tool to analyze a patient’s CT scan. The tool flags a suspicious nodule and outputs a probability score suggesting a 78% likelihood of malignancy. The physician communicates the finding to the patient and recommends biopsy. The patient asks: “How does the AI know that?” The physician cannot fully explain the algorithm’s reasoning — the model is a deep neural network whose internal logic is not readily interpretable, even to the radiologist who relies on it.

This is the black box disclosure problem in clinical AI, and it sits at the intersection of three distinct legal frameworks: the informed consent doctrine, medical malpractice liability, and anti-discrimination law. Each framework is under pressure from AI deployment patterns that existing legal doctrine was not designed to address.

For healthcare providers, hospital systems, and health AI technology companies, the black box problem is not a theoretical concern. It is an active liability exposure whose dimensions are still being defined by courts, regulators, and legislators — and whose practical management requires deliberate clinical and legal design choices made before the patient-physician conversation, not during it.

Informed Consent: The Doctrinal Foundation

Informed consent is among the most fundamental principles in American medical law. The doctrine requires that a physician, before proceeding with a diagnostic procedure or treatment, disclose to the patient the material risks and benefits of the proposed course of action, the alternatives available, and the risks and benefits of those alternatives. The patient then makes a voluntary, informed decision whether to proceed.

The materiality standard varies by jurisdiction. Most states apply either the professional standard (what a reasonable physician would disclose) or the patient standard (what a reasonable patient would want to know in deciding whether to accept or refuse the proposed treatment). Approximately half the states apply each standard.

Under either test, the question for AI-assisted diagnosis is the same: is the fact that an AI system contributed to or generated the diagnostic recommendation material information that a reasonable patient would want disclosed before consenting to proceed?

What Current Law Requires

As of mid-2026, there is no federal statutory requirement that physicians disclose AI involvement in diagnosis or treatment planning as a component of the informed consent process, absent specific state legislation. The traditional informed consent doctrine was developed in a world of physician-driven diagnosis, and its requirements as applied to AI tools are still being worked out in practice and litigation.

However, that does not mean the legal exposure is theoretical. Several specific scenarios create concrete informed consent risk today.

AI limitations as material risks. Informed consent requires disclosure of material risks — including diagnostic error rates. If an AI diagnostic tool has known performance limitations in specific patient populations (lower accuracy for patients of a particular age, sex, skin tone, or comorbidity profile), those limitations are arguably material risks that a reasonable patient would want to know when deciding whether to accept a diagnosis derived in part from that tool.

The explainability gap as a consent barrier. When a physician cannot explain to a patient why the AI reached its conclusion — because the model’s internal logic is genuinely opaque — the physician cannot provide the kind of disclosure that allows the patient to make a meaningfully informed decision. A patient who cannot understand the basis for a recommendation cannot evaluate it. The consent that results from that process may be legally valid in form but inadequate in substance.

Requests for disclosure. If a patient directly asks whether AI was used in their diagnosis, the physician cannot ethically or legally deny it. An affirmative misrepresentation — telling a patient no AI was used when AI was in fact used — creates both a fraud exposure and a consent defense in subsequent malpractice litigation.

State Disclosure Requirements

Some states have moved beyond the common law doctrine and enacted explicit AI disclosure requirements in clinical settings. California requires healthcare facilities and physician offices to disclose generative AI use in patient communications about clinical information, unless a licensed provider has reviewed and approved the content before it reaches the patient. Texas mandates human review of AI outputs in electronic health records and requires informing patients when AI assists in diagnosis or treatment.

These state-specific requirements are evolving rapidly. Healthcare providers and health technology companies that deploy in multiple states need to track this landscape as a compliance matter, not just an ethical one.

Liability Architecture: Following vs. Overriding AI Recommendations

The most immediate and practically significant liability question in clinical AI is not about disclosure — it is about what happens when the AI is wrong and how physician behavior in response to the AI’s recommendation affects the liability analysis.

The current legal framework creates a two-sided liability trap that physicians and the institutions deploying AI tools need to understand clearly.

The Liability for Following AI: Blind Reliance

A physician who follows an AI recommendation without exercising independent clinical judgment and the AI recommendation turns out to be wrong faces malpractice liability. Courts have consistently held that the standard of care requires physicians to independently assess the clinical situation. An AI tool is not a licensed clinician. It does not bear the legal obligation to the patient that the physician bears. The physician cannot transfer that obligation to the algorithm.

Multiple medical liability carriers and healthcare law commentators have flagged what they call “automation bias” — the documented tendency of clinicians to defer to algorithmic outputs even when their own clinical judgment or available evidence might suggest a different conclusion. When automation bias leads a physician to accept an erroneous AI output without adequate scrutiny, and harm results, the physician’s failure to exercise independent judgment is the proximate cause of the harm.

Critically, a physician cannot defend against a malpractice claim by arguing that the AI told them the diagnosis was correct. “The algorithm said so” is not a defense to a failure-to-exercise-professional-judgment claim. If anything, courts and juries are likely to view over-reliance on an algorithm — a documented failure mode that physicians are now expected to be aware of — as evidence of negligence.

The Liability for Overriding AI: The New Standard of Care Problem

The flip side is more complex and, for physicians, potentially more troubling as AI adoption accelerates.

If an AI diagnostic tool has a documented performance record significantly better than the average physician’s accuracy in a given domain — radiology reading, skin lesion classification, ECG interpretation — then the tool’s output begins to influence the standard of care. A physician who overrides a high-confidence AI recommendation without adequate clinical justification, and who is wrong, may face a malpractice theory based on failure to give appropriate weight to available diagnostic evidence.

This is not yet a settled area of law. No landmark case has clearly established that a physician’s failure to follow an AI recommendation constitutes malpractice. But the trajectory is clear: as AI diagnostic tools become more validated, more widely adopted, and more demonstrably accurate, failing to use them at all — or systematically ignoring their outputs — will increasingly be viewed as a deviation from the standard of care.

The emerging framework for physician liability in AI-assisted diagnosis therefore looks like this: the physician must use available AI tools appropriately, exercise independent clinical judgment in evaluating AI outputs, be able to articulate the basis for agreeing with or departing from an AI recommendation, and document that reasoning in the medical record. Neither blind reliance nor reflexive dismissal is defensible.

Documentation as Liability Management

One implication of this framework that every physician and hospital needs to internalize: the medical record must reflect not just the clinical decision, but the physician’s engagement with the AI tool and independent clinical reasoning.

A medical record that says “AI imaging analysis suggested 78% malignancy probability; I reviewed the imaging independently, considered the patient’s clinical history, and concur with biopsy recommendation” creates a very different liability profile than a record that says nothing about AI involvement at all. The second record may leave the physician unable to demonstrate, in subsequent litigation, that they exercised the independent judgment the standard of care requires.

Algorithmic Bias as an Undisclosed Material Risk

The black box disclosure problem has a second dimension that is less discussed but equally significant: AI diagnostic tools trained on non-representative data can perform significantly worse for certain patient populations than for others. That differential performance is a material risk. In most clinical deployments, it is not disclosed.

The Training Data Problem

AI diagnostic models are trained on historical data. If the historical data reflects existing disparities in who received care, what diagnoses were recorded, and how diseases presented in different populations, the model will replicate and potentially amplify those disparities. A model trained predominantly on imaging data from white male patients may perform less accurately when applied to female patients, elderly patients, or patients from racial or ethnic minority groups.

This is not a hypothetical concern. Documented examples include pulse oximetry algorithms that perform less accurately for patients with darker skin tones, dermatology AI tools trained primarily on images of lighter skin, and cardiac risk models that underestimate risk in women because the historical data reflected patterns in a predominantly male patient population.

The legal relevance of these disparities is significant and growing. Under the informed consent doctrine, known limitations of a diagnostic tool that affect its reliability for a specific patient may be material information that the physician must disclose. A physician who uses a dermatology AI tool known to have substantially lower accuracy for darker skin tones on a patient of color, without disclosing that limitation, has arguably failed to provide informed consent — even if the physician is individually unaware of the disparity.

Anti-Discrimination Law

Beyond informed consent, algorithmic bias in clinical AI raises anti-discrimination liability under Section 1557 of the Affordable Care Act, which prohibits discrimination in healthcare on the basis of race, color, national origin, sex, age, and disability. A new Section 1557 rule that took effect with a May 2025 compliance deadline explicitly addresses AI-based clinical decision tools, prohibiting their use in ways that result in discriminatory outcomes even absent discriminatory intent.

The practical implication: health systems and providers deploying AI diagnostic tools should be conducting demographic performance audits — testing whether the tool performs comparably across the patient populations they serve. Deploying a tool without having done that analysis, and with no mechanism for identifying performance disparities after deployment, creates both anti-discrimination liability and an informed consent failure for the patients most affected.

What Disclosure Looks Like in Practice

The challenge is that many AI tool vendors do not readily disclose training data composition, validation demographics, or differential performance statistics. A hospital or health system that has purchased an AI diagnostic tool may not have the information needed to evaluate whether demographic performance disparities exist, let alone to disclose them to patients.

This creates a vendor relationship and procurement obligation. Before deploying an AI diagnostic tool in clinical practice, health system procurement processes should require vendors to produce:

• Training data composition and demographic distribution
• Validation study populations and performance metrics stratified by relevant demographic groups
• Known performance limitations and the populations where accuracy has been demonstrated to be lower
• The vendor’s monitoring protocols for identifying performance drift or emerging disparities post-deployment

If a vendor cannot or will not provide this information, that is relevant data about the clinical appropriateness of deploying the tool.

Designing for Disclosure: Practical Approaches

The legal risks in clinical AI informed consent are real, but they are manageable with deliberate design. The following framework reflects the current state of the law and where it is heading.

Institutional Disclosure Policies

Hospital systems and large practices should develop institutional disclosure policies that establish a default approach to AI disclosure in the informed consent process. The policy should address:

• What categories of AI tools (diagnostic imaging AI, clinical decision support, risk stratification models) require disclosure as part of informed consent
• What the disclosure should communicate: that AI was used, what it assessed, and what the physician’s independent clinical assessment concluded
• How to handle patient questions about AI involvement, including the “I cannot fully explain the algorithm’s reasoning” scenario
• Documentation standards for AI-involved clinical encounters

A well-designed disclosure policy protects both patients and providers. It gives patients the information they need to make genuinely informed decisions. It gives providers a documented basis for demonstrating, in subsequent litigation, that they disclosed appropriately and exercised independent clinical judgment.

Explainability Requirements in Procurement

Health technology companies and health systems procuring AI diagnostic tools should prioritize tools that offer clinician-facing explanations — not just probability scores, but an indication of which clinical features contributed most to the output. These explanations do not need to be mathematically precise. They need to be clinically meaningful, so that the physician can evaluate whether the AI’s reasoning aligns with the clinical picture.

Where genuinely black box models are used, the institutional policy should reflect the explainability limitation and require physicians to document more extensive independent clinical reasoning to compensate.

Consent Form Language

For AI tools that play a material role in diagnosis or treatment planning, consent forms should be updated to reflect AI involvement. Language along these lines is appropriate: “Your care team may use computer-assisted analysis tools, including artificial intelligence-based diagnostic software, as part of your evaluation. All findings from these tools are reviewed and interpreted by your physician, who makes all clinical recommendations based on their independent professional judgment.”

This disclosure is not legally complex, but it needs to be in the form and needs to be reviewed with the patient, not just presented as boilerplate.

The Road Ahead

The law of AI informed consent in clinical settings is in early development. The cases that will define it are beginning to work their way through courts. The state legislation that will codify it is being drafted in multiple legislatures simultaneously. Federal agency guidance is forthcoming.

Healthcare providers and health AI companies that wait for the doctrine to fully crystallize before designing their disclosure and liability management practices will find that the law caught up with them in the form of a claim or enforcement action, rather than in a planning memo. The underlying principles — that patients are entitled to information material to their decisions, that physicians must exercise independent clinical judgment, and that AI systems must be deployed without discrimination — are already established law. Their application to AI diagnostic tools is following, and it is following quickly.

Building the clinical, documentation, and procurement practices that reflect those principles now, before the first wave of AI malpractice verdicts reshapes them under compulsion, is both the legally prudent and the ethically right course.

This post is for general informational purposes only and does not constitute legal advice. Reading this post does not create an attorney-client relationship. If you have questions about your specific situation, consult a qualified attorney.